MELBOURNE, Australia--(BUSINESS WIRE)--Anadis Ltd (ASX:ANX; OTC:ANDIY), a biopharmaceutical company focused on research, development and production of immune milk (colostrum)-derived polyclonal antibodies and other proteins to address major diseases, today announces the initiation of a clinical trial with top clinical scientists at Tel Aviv Sourasky Medical Center in Israel. The clinical trial will explore the efficacy of a formulation developed by Anadis to address the symptoms of Inflammatory Bowel Disease (IBD), a serious chronic condition effecting millions of persons annually.
